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Poster Session I S249matching pairs. The primary clinical outcomes were time to progres-
sion (TTP), progression-free survival (PFS), and overall survival
(OS), all defined from the time of auto-HCT. Stratified Log-rank
test and Cox proportional hazards model stratified on matched pairs
were conducted on TTP, PFS and OS.
Results: Patient characteristics are summarized in the attached
Table. NSM and SM groups were not different by age at auto-
HCT, time from diagnosis to auto-HCT, race, sex, and serum
creatinine at auto-HCT (Table). Patients with SM had higher
percentage of bone marrow plasma cells at auto-HCT. Median
follow-up time was 37 months. Median TTP was 29 months and
31 months for the NSM and SM groups, respectively. Median
PFS was 16 months and 29 months for the NSM and SM groups,
respectively. Median OS was 45 and 67 months in the NSM and
SM groups, respectively. There was no difference in TTP, PFS
and OS between NSM and SM after adjusting for conditioning
regimen or time from diagnosis to transplant in the multivariate
models (p-Value .0.69).
Conclusion: In this large single center study the outcome of pa-
tients with NSM was comparable to patients with SM after an
auto-HCT.
Table. Association between patients characteristics and
histology
Covariate Levels NSM SM p-ValueAge at diagnosis age< 5 54.25 (median) 17 (54.8%) 45 (47.9%) 0.478age>54.25 14 (45.2%) 49 (52.1%)Age at transplant age < 5 55.17(median) 17 (54.8%) 45 (47.9%) 0.4625age >55.17 14 (45.2%) 49 (52.1%)Age at transplant <40 1 (3.2%) 2 (2.1%) 0.807240-49 7 (22.6%) 24 (25.5%)50-59 16 (51.6%) 48 (51.1%)> 5 60 7 (22.6%) 20 (21.3%)Time from diagnosis
to transplant>8months 12 (38.7%) 43 (45.7%) 0.2863< 5 8 months 19 (61.3%) 51 (54.3%)Racial Group Black 3 (9.7%) 11 (12%) 0.2849Mixed 4 (12.9%) 25 (27.2%)White 24 (77.4%) 56 (60.9%)Sex F 14 (45.2%) 34 (36.2%) 0.3010M 17 (54.8%) 60 (63.8%)Plasmacytoma No 24 (77.4%) 70 (75.3%) 0.7646Yes 7 (22.6%) 23 (24.7%)Creatinine < 5 1 13 (52%) 36 (48%) 0.3242>1 12 (48%) 39 (52%)Plasma cell%
pre-transplant< 5 10% 9 (34.6%) 14 (17.5%) 0.0561>10% 17 (65.4%) 66 (82.5%)122
PEGFILGRASTIM VS FILGRASTIM-BASED STEADY STATE AUTOLOGOUS
HSC MOBILIZATION IN THE SETTING OF PATIENT ADAPTED (‘‘JUST IN
TIME’’) PLERIXAFOR: EFFICACY AND ECONOMIC OUTCOMES
Costa, L.J., Kramer, C., Hogan, K.R., Butcher, C.D., Littleton, A.,
Shoptaw, K.B., Kang, Y., Stuart, R.K. Medical University of South Car-
olina, Charleston, SC
Plerixafor enhances the ability of filgrastim to mobilize CD34+
cells for AHSCT in patients with lymphoma (LY) or multiple my-
eloma (MM). Single dose of pegfilgrastim has, in some series,
been utilized for autologous mobilization for its convenience
and possibly greater efficacy. We retrospectively compared two
consecutive mobilization cohorts utilizing filgrastim (FIL) 10
mcg/kg/day or pegfilgrastim (PEG) 12 mg (single dose) for steady
state mobilization and the same algorithm for ‘‘just in time’’ use of
plerixafor. In both cohorts peripheral blood CD34+ cells (PB-
CD34+) enumeration was performed on the 4th day after initia-
tion of growth factor to determine the immediate initiation of
apheresis or administration of plerixafor with apheresis starting
in the next day. Decision to use plerixafor was determined by
the same previously validated algorithm in both cohorts. Apheresis
and growth factor +/- plerixafor were continued until the mobili-
zation target was met. Analysis of estimated total cost of mobili-zation utilized average wholesale price (AWP) for drugs and
average charges for apheresis, cryopreservation and laboratory
tests from a representative sample of subjects. Seventy-four con-
secutive subjects were included in FIL and 57 in PEG. The two
cohorts were comparable in terms of age (57.5 vs. 53.7), propor-
tion of patients with diagnosis of MM (63.5% vs.66.7%), propor-
tion of MM patients previously exposed to lenalidomide (63.8%
vs. 50%), average body weight (82.9 vs.84 kg) and average mobi-
lization target (4.5 vs. 5 x 106 CD34+/kg). Overall 68/74 in FIL
and 52/57 patients in PEG met the mobilization target. Median
PB-CD34+ on day 4 was significantly higher in PEG.
Table. Mobilization outcomes
FIL PEGPN 5 74 N 5 57Day 4 PB-CD34+ 18.1 (+/-19.5) 28.7 (+/-27) 0.01
Patients requiring plerixafor 50 (67.5%) 26 (45.6%) 0.01
Number of days of apheresis 1.62 (+/-0.72) 1.68 (+/-0.65) 0.6
Number of injections 13.1 (+/-3.8) 2.7 (+/-0.9) 0.001
Number of CD34+ cells
collected (x10e6/kg)7.26 (+/-3.99) 7.54 (+/-3.52) 0.6Patients meeting
mobilization target68 (91.9%) 52 (91.2%) 1Mobilization failures (<2 x 10e6
CD34+/kg)1 (1.3%) 1 (1.7%) 1Patients in PEG received fewer subcutaneous injections and
were less likely to require administration of plerixafor. Cohorts
had near identical average number of apheresis sessions and com-
parable CD34+ yield. The estimated cost associated with growth
factor was on average US$3,069 higher in PEG, but it was coun-
terbalanced by an estimated $3,546 saving in plerixafor, resulting
in no significant difference in the estimated overall cost of mobi-
lization. Single administration of pegfilgrastim is associated with
better CD34+ mobilization than daily filgrastim in patients with
MM and LY allowing for effective mobilization with less frequent
use of plerixafor. Pegfilgrastin with patient adapted used of plerix-
afor is a reliable, convenient and cost-neutral strategy for AHSC
mobilization.123
HIGH DOSE CHEMOTHERAPY (HDT) WITH BUSULFAN, MELPHALAN AND
TOPOTECAN FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION (ASCT) IN PEDIATRIC PATIENTS (pts) WITH HIGH
RISK SOLID TUMORS
Pawlowska, A.B.1, Wolfson, J.A.1, Cheng, J.2, Sorrell, A.1, Sato, J.1,
Anderson, C.1, Hitt, D.1, Suarez, M.1, Forman, S.J.3, Rosenthal, J.1
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The prognosis of pts with high risk solid tumors remains poor de-
spite advances in multimodal and high dose radiation and chemo-
therapy.
HDT followed by ASCT appears to provide survival benefit to
a select group of pts. We hypothesize that patients with chemo-sen-
sitive solid tumors with poor risk features at diagnosis or with recur-
rent metastatic disease will have lower morbidity and improved
survival with a conditioning regimen using a novel combination of
busulfan, melphalan and topotecan (B-M-T) followed by ASCT.
In this pilot study pts received topotecan continuous infusion in
combination with busulfan (pharmacokinetics (PK) based dose ad-
justment) and melphalan. The primary outcome of interest was the
toxicity of combined HDT with B-M-T. Secondary objectives
were to evaluate engraftment, survival and PK of busulfan and top-
otecan. Twenty-two patients aged 2.2-27 years (median 8.8 yrs)
were treated on the B-M-T protocol at City of Hope from 5/2007
to 4/2011. Diagnoses included Ewing sarcoma (n 5 8), neuroblas-
toma (n5 7),Wilms (n5 3), rhadbomyosarcoma (n5 3) andmedul-
loblastoma (n 5 1). Seven pts were in complete remission, while 15
